48,975
edits
Difference between revisions of "Apocrine carcinoma of the breast"
Jump to navigation
Jump to search
Apocrine carcinoma of the breast (view source)
Revision as of 11:38, 8 September 2016
, 11:38, 8 September 2016no edit summary
| (6 intermediate revisions by 2 users not shown) | |||
| Line 9: | Line 9: | ||
| LMDDx = [[glycogen-rich clear cell carcinoma of the breast]] | | LMDDx = [[glycogen-rich clear cell carcinoma of the breast]] | ||
| Stains = | | Stains = | ||
| IHC = AR +ve, [[GCDFP-15]] +ve, ER -ve, PR -ve | | IHC = AR +ve, [[GCDFP-15]] +ve, ER -ve, PR -ve, HER2 +ve/-ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Grossing = | | Grossing = [[breast grossing]] | ||
| Staging = [[breast cancer staging]] | |||
| Site = [[breast]] - see ''[[invasive breast cancer]]'' | | Site = [[breast]] - see ''[[invasive breast cancer]]'' | ||
| Assdx = | | Assdx = | ||
| Line 38: | Line 39: | ||
==Microscopic== | ==Microscopic== | ||
Features:<ref name=Ref_BP217>{{Ref BP|217}}</ref> | Features:<ref name=Ref_BP217>{{Ref BP|217}}</ref> | ||
*Prominent [[nucleoli]]. | *Prominent red [[nucleoli]]. | ||
**Often multiple.<ref>{{Cite journal | last1 = O'Malley | first1 = FP. | last2 = Bane | first2 = A. | title = An update on apocrine lesions of the breast. | journal = Histopathology | volume = 52 | issue = 1 | pages = 3-10 | month = Jan | year = 2008 | doi = 10.1111/j.1365-2559.2007.02888.x | PMID = 18171412 }}</ref> | **Often multiple.<ref>{{Cite journal | last1 = O'Malley | first1 = FP. | last2 = Bane | first2 = A. | title = An update on apocrine lesions of the breast. | journal = Histopathology | volume = 52 | issue = 1 | pages = 3-10 | month = Jan | year = 2008 | doi = 10.1111/j.1365-2559.2007.02888.x | PMID = 18171412 }}</ref> | ||
*Abundant granular eosinophilic cytoplasm. | *Abundant granular eosinophilic cytoplasm. | ||
| Line 47: | Line 48: | ||
*Cutaneous Apocrine Carcinoma | *Cutaneous Apocrine Carcinoma | ||
***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum. | ***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum. | ||
*Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR-ve).<ref name=pmid23245877/> | *Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR -ve).<ref name=pmid23245877/> | ||
===Images=== | ===Images=== | ||
| Line 63: | Line 64: | ||
==IHC== | ==IHC== | ||
Smaller tumours classically:<ref name=pmid16045781>{{Cite journal | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref> | Smaller tumours classically:<ref name=pmid16045781>{{Cite journal | last1 = Honma | first1 = N. | last2 = Takubo | first2 = K. | last3 = Akiyama | first3 = F. | last4 = Sawabe | first4 = M. | last5 = Arai | first5 = T. | last6 = Younes | first6 = M. | last7 = Kasumi | first7 = F. | last8 = Sakamoto | first8 = G. | title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. | journal = Histopathology | volume = 47 | issue = 2 | pages = 195-201 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02181.x | PMID = 16045781 }}</ref> | ||
*AR +ve. | *[[Androgen receptor|AR]] +ve. | ||
*[[GCDFP-15]] +ve. | *[[GCDFP-15]] +ve. | ||
Usually:<ref name=Ref_BP217>{{Ref BP|217}}</ref> | Usually:<ref name=Ref_BP217>{{Ref BP|217}}</ref> | ||
*ER -ve. | *ER -ve. | ||
*PR -ve. | *PR -ve. | ||
* | *Often HER2 +ve but can be HER2 -ve.<ref name=pmid19898421>{{Cite journal | last1 = Niemeier | first1 = LA. | last2 = Dabbs | first2 = DJ. | last3 = Beriwal | first3 = S. | last4 = Striebel | first4 = JM. | last5 = Bhargava | first5 = R. | title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. | journal = Mod Pathol | volume = 23 | issue = 2 | pages = 205-12 | month = Feb | year = 2010 | doi = 10.1038/modpathol.2009.159 | PMID = 19898421 }}</ref> | ||
Notes | Notes: | ||
*Salivary | *[[Salivary duct carcinoma]] and cutaneous adnexal tumours can show a similar IHC profile. | ||
*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' <ref>{{Cite journal | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref> | *Apocrine carcioma can be a non-basal type 'triple negative carcinoma'.<ref name=pmid22450930>{{Cite journal | last1 = Tsutsumi | first1 = Y. | title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. | journal = Jpn J Clin Oncol | volume = 42 | issue = 5 | pages = 375-86 | month = May | year = 2012 | doi = 10.1093/jjco/hys034 | PMID = 22450930 }}</ref> | ||
**May show different behaviour to other types of triple negative carcinoma | **May show different behaviour to other types of triple negative carcinoma. | ||
**May respond to treatments targeting the androgen receptor<ref>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }} | **May respond to treatments targeting the androgen receptor.<ref name=pmid25310144>{{Cite journal | last1 = Safarpour | first1 = D. | last2 = Tavassoli | first2 = FA. | title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. | journal = Arch Pathol Lab Med | volume = | issue = | pages = | month = Oct | year = 2014 | doi = 10.5858/arpa.2014-0122-RA | PMID = 25310144 }}</ref> | ||
</ref> | |||
*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma. | *Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma. | ||
*Many ductal carcinomas, NOS | *Many [[invasive ductal carcinoma of the breast|ductal carcinomas, NOS]] show AR positivity but are often ER +ve. | ||
==See also== | ==See also== | ||